Sunday, September 18, 2016

BRCA, Rucaparib - and Clovis Pharmaceuticals

At the great Sisters, Oregon quilting frenzy
As no doubt you deduced many months ago, the oft-used acronym BRCA stands for Breast Cancer; medical researcher types seem to like to like to paste together the first two letters of words to designate something.  That, for example, the famous HELA strain of cancer cells received its name from an equally famous patient named Henrietta Lax. 

Anyway, you really don’t want mutated BRCA1 or BRCA2 genes, because they accompany (cause?) a high susceptibility to breast – and, as it turns out – ovarian cancer.  But, if you DO have OVCA (see: ovarian cancer, OVCA) you should then hope that you are  BRCA-positive, because (for reasons I don’t understand) BRCA-positive cases are easier to treat.  The article cited below relates how rucaparib, a PARP inhibitor developed by Clovis Pharmaceuticals has been so successful in treating women with advanced BRCA-positive OVCA that it has been granted fast-track status by the NCI and FDA.  If you know someone in that unfortunate category, tell them to hound their oncodoc to get them in a trial.


Yes, I thought I had read this “news” before – and written about it.  17 months ago!  Boy, Clovis must have a skillful publicity guy!





No comments:

Post a Comment